After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset
Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over the Amgen drug that is currently the only approved treatment.
